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Introduction
Alzheimer disease (AD) is the most common neurodegenerative dementia, affecting
an estimated 5.4 million people1 and costing as much as $214 billion annually in the
US alone.2 New cases of AD continue to increase at an alarming rate worldwide,
and its economic and health burden are projected to expand substantially in the next
50 years.3 Currently, there is no cure for AD. US Food and Drug Administration (FDA)approved medications, including three cholinesterase inhibitors and one noncompetitive

63

submit your manuscript | www.dovepress.com

Open Access Journal of Clinical Trials 2015:7 63–76

Dovepress

© 2015 Holroyd et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on
how to request permission may be found at: http://www.dovepress.com/permissions.php

http://dx.doi.org/10.2147/OAJCT.S81542
Powered by TCPDF (www.tcpdf.org)

Background: There are currently few available treatments and no cure for Alzheimer disease
(AD), a growing public health burden. Animal models and an open-label human trial have
indicated that deep brain stimulation (DBS) of memory circuits may improve symptoms and
possibly slow disease progression. The ADvance trial was designed to examine DBS of the
fornix as a treatment for mild AD.
Methods: ADvance is a randomized, double-blind, placebo-controlled, delayed-start, multicenter clinical trial conducted at six sites in the US and one site in Canada. Eighty-five subjects initially consented to be screened for the trial. Of these, 42 subjects who met inclusion
and exclusion criteria were implanted with DBS leads anterior to the columns of the fornix
bilaterally. They were randomized 1:1 to DBS “off ” or DBS “on” groups for the initial 12 months
of follow-up. After 1 year, all subjects will have their devices turned “on” for the remainder
of the study. Postimplantation, subjects will return for 13 follow-up visits over 48 months for
cognitive and psychiatric assessments, brain imaging (up to 12 months), and safety monitoring.
The primary outcome measures include Alzheimer’s Disease Assessment Scale – cognitive
component (ADAS-cog-13), Clinical Dementia Rating sum of boxes (CDR-SB), and cerebral
glucose metabolism measured with positron emission tomography. This report details the study
methods, baseline subject characteristics of screened and implanted participants, and screento-baseline test–retest reliability of the cognitive outcomes.
Results: Implanted subjects had a mean age of 68.2 years, were mostly male (55%), and
had baseline mean ADAS-cog-13 and CDR-SB scores of 28.9 (SD, 5.2) and 3.9 (SD, 1.6),
respectively. There were no significant differences between screened and implanted or nonimplanted subjects on most demographic or clinical assessments. Implanted subjects had significantly lower (better) ADAS-cog-11 (17.5 vs 21.1) scores, but did not differ on CDR-SB. Scores
on the major outcome measures for the trial were consistent at screening and baseline.
Conclusion: ADvance was successful in enrolling a substantial group of patients for this novel
application of DBS, and the study design is strengthened by rigorous subject selection from
seven sites, a double-blind placebo-controlled design, and extensive open-label follow-up.
Keywords: deep brain stimulation, Alzheimer disease, fornix, methods, clinical trials
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N-methyl-d-aspartic acid receptor antagonist, temporarily
ameliorate some symptoms in a subset of patients.1 Phase II
and III trials of putative disease-modifying therapies targeting
the amyloid protein aggregations observed in AD have largely
been unsuccessful in preventing disease progression.4–7 Additionally, the long-term safety of these treatments remains to
be determined. Clearly, there is a great need for more specific
and efficacious therapies for AD.
Converging evidence from neuropathological and in vivo
imaging studies has demonstrated the vulnerability of the
hippocampus and heteromodal association cortices in AD, as
well as decreased functional connectivity in cortico-cortical
and cortico-hippocampal circuits.8,9 Approaching AD as
a dysfunction in cortico-cortical and cortico-hippocampal
circuits suggests that modulating neuronal activity within
these networks may be a viable treatment option for early
AD. Deep brain stimulation (DBS) is a neurosurgical technique that has shown success modulating pain,10 motor
dysfunction,11,12 and mood13,14 circuits in conditions for which
pharmacologic treatments are not effective. The importance
of developing circuitry-based therapeutic approaches to
modulate cortical and hippocampal networks affected in AD
was the impetus for a Phase I study of DBS of the fornix in
early AD patients.15
The fornix is a white matter bundle that connects the
hippocampus with other components of the limbic system,16,17
forming circuits that have been implicated in episodic
memory.18,19 Recent diffusion tensor imaging (DTI) studies
have shown white matter reductions in the fornix of individuals with AD.20 In fact, fornix atrophy may precede both
hippocampal degeneration and clinical symptoms of AD and
predict conversion from mild cognitive impairment (MCI)
to AD.21,22 This growing body of evidence, combined with
rodent studies showing that DBS of the Papez circuit improves
memory and promotes neurogenesis,23,24 indicates that DBS
targeting of the fornix region (DBS-f) may be an effective
treatment for AD symptoms. In the open-label Phase I trial of
six AD subjects treated with DBS-f for 12 months, positron
emission tomography (PET) scans showed an increase in
cortical glucose metabolism and increased cortical functional connectivity over 1 year15 in contrast to the decreases
in cortical metabolism and functional connectivity typically
observed in AD.25–27
Building on the aforementioned collective observations,
ADvance was designed as a double-blind placebo-controlled
clinical trial to preliminarily assess the safety and efficacy
of DBS-f for the treatment of very mild AD, as well as the
utility of prespecified clinical and neuroimaging baseline
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measures as predictors of response. While other targets
along the Papez circuit could, at least in theory, be suitable or perhaps more optimal, we chose a target within the
hypothalamus which contains both the descending portion
of the fornix and the mammillary body. This was done based
on our empirical observation of acute memory effects in a
patient with hypothalamic stimulation for obesity28 and the
preliminary observations in the six AD patients in the pilot
study of DBS for AD.15 Other potential targets would require
validation of both safety and efficacy, something that was
beyond the scope of our trial. Here, we describe the design
and methods of the ADvance clinical trial and discuss the
reliability of the major clinical outcome measures used in
the study.

Methods
Overview
ADvance (ClinicalTrials.gov identifier: NCT01608061) is a
feasibility clinical trial funded by the National Institute on
Aging (R01AG042165) and Functional Neuromodulation
Ltd (FNM). Six sites in the United States and one in Canada
participated in enrollment (see “Acknowledgments” section).
Sites were chosen based on previous experience with clinical
research related to AD, neuroimaging capabilities, ethical
approvals, and experience with DBS research.
ADvance is a 12-month double-blind, placebo-controlled,
masked clinical trial, as shown in Figure 1. Consenting
individuals participated in a screening visit followed by
a baseline visit to assess eligibility and collect baseline
cognitive and other clinical assessments, historical documents, laboratory values, and neuroimaging. DBS device
implantation took place within 60 days of consent. Two
weeks following implantation, participants were randomized
into two groups, DBS “on” or DBS “off ”, for a 12-month
blinded period followed by a 12-month open-label extension
during which all subjects will be programmed to DBS “on”.
Additional long-term clinical follow-up for up to 48 months
will be provided.

Participants: inclusion
and exclusion criteria
Inclusion

• Informed consent signed by the subject, caregiver, and a
surrogate
• Nonchildbearing/postmenopausal women, and men
between 45 and 85 years of age
• Met criteria for probable AD according to the National
Institute of Aging/Alzheimer’s Association criteria29
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Screening
(informed consent)

ERC
Enrollment Review Committee

Baseline
(informed consent)

Safety and
interim efficacy
assessments

Key
assessments
safety and
efficacy

1, 3, 6, 9 mo

12 mo

13, 15, 18, 21,
24, 36, 48 mo

On

On

On

On

Off

Off

Off

On

Implantation
n=42

Ongoing safety

Randomization
day 14

Figure 1 Flow diagram depicting an overview of the ADvance trial schedule. Major visits are shown along with the number of participants at implantation (n=42). Green
indicates DBS “on”, red indicates DBS “off ”.
Abbreviations: mo, months; DBS, deep brain stimulation.

• Clinical Dementia Rating scale (CDR global) rating of
0.5 or 1 at screening30
• Alzheimer’s Disease Assessment Scale – cognitive component (ADAS-cog-11) score of 12–24, inclusive, with
a score $4 on ADAS-cog item 1 (immediate recall) at
both screening and baseline visits30,31
• General medical health rating $3 (good or excellent)32
• Living at home with an available caregiver or informant to
report on daily activities and function throughout the study
• Fluent in English
• Good surgical candidate for placement of a deep brain
stimulator, as determined by the neurosurgical team
• On a stable dose of a acetylcholinesterase inhibitor
(AChEI) donepezil, galantamine, or rivastigmine for at
least 60 days prior to signing informed consent, without
intention to modify this medication dose throughout the
entirety of the study.

•
•
•
•

•
•

•

•

Exclusions
• Neuropsychiatric Inventory (NPI) total score $10 or
score $4 in any domain except apathy at screening
• Modified Hachinski ischemic score .4 at screening34
• Young Mania Rating Scale (YMRS) $11 at screening35
• Attempted suicide in the 2 years prior to signing consent
• Risk for suicide as determined by an answer of “yes” to
“suicidal ideation” or “yes” to any items in the suicidal
33

Open Access Journal of Clinical Trials 2015:7

•

•

behavior section with reference to the 3-month period
prior to screening on the Columbia Suicide Severity
Rating Scale (C-SSRS)36
Current major psychiatric disorder
Score .10 on the Cornell Scale for Depression and
Dementia (CSDD) at screening37
History of head trauma in the 2 years prior to signing
consent
History of brain tumor, subdural hematoma, or other clinically significant space-occupying lesions on CT (computed
tomography) or MRI (magnetic resonance imaging)
Mental retardation
Current alcohol or substance use disorder as defined by
Diagnostic and Statistical Manual of Mental Disorders,
fourth edition – text revision (DSM-IV-TR)
Exclusions for PET and MRI, including claustrophobia,
metal implanted in the body (MRI), and insulin-dependent
diabetes (PET)
Radiation exposure in the year prior to consent that
added to exposure in the study would exceed 5 rem over
12 months
Any abnormal laboratory results, cardiovascular or neurovascular disorders, or currently prescribed non-AD medications that would preclude participation in the study
Unstable doses of any medication prescribed for the
treatment of memory loss or AD
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• Unwilling or unable to comply with the protocol
• Life expectancy of ,1 year
• Actively enrolled in another concurrent clinical trial.
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Recruitment and consent
Participants were recruited from memory and geriatric psychiatry clinics, advertising, and community outreach activities at each of the seven sites. Prospective participants were
first assessed for their ability to provide consent through clinical interviews. Clinicians experienced in dementia research
and DBS surgery evaluated each participant’s ability to comprehend the consent form as well as understand the personal
consequences of what would and could happen during the
study. Assessments and consent procedures took place in the
presence of a caregiver who cosigned the consent form as a
witness. Voluntary written informed consent by each subject
and his or her caregiver was required at the beginning of both
the screening and baseline visits and prior to surgical implant
procedure (if all entry requirements were met).

Eligibility screening
Enrollment was defined as the time a subject signed the
screening informed consent to participate and was followed
by an initial screening visit at which medical and neuropsychiatric information was gathered (Table 1). In order to move
forward with implantation, a site-independent Enrollment
Review Committee (ERC) reviewed the data collected to
determine if subjects met inclusion and exclusion criteria.
For each subject, the ERC reviewed historical documentation
of early AD as well as scores on cognitive tests conducted
during the screening visit to confirm the diagnosis of probable
AD. They also verified the absence of concomitant medical or
psychiatric conditions or medications, and any surgical risks
that might affect DBS surgery. Additionally, US trial sites
audio-recorded selected psychometric assessments, and siteindependent ERC raters dually scored a randomly selected
sample of ADAS-cog and CDR interviews to confirm scoring
accuracy and rater consistency.

Baseline visit and DBS
device implantation
Baseline visit and surgery

A baseline visit was scheduled #59 days postconsent at
which baseline medical, laboratory, neuropsychological, and
imaging data (PET and MRI) were obtained (Table 1).
Implantation surgery took place within 60 days following screening consent if all study requirements were met.
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High-resolution, stereotactic MRI scans of the brain were
used to directly target the bilateral postcommissural fornices.
More specifically, the DBS electrode was implanted 2 mm
anterior and parallel to the vertical portion of the fornix
within the hypothalamus (Figure 2). The most ventral contact of the DBS lead (Medtronic model 3387) was typically
placed posteromedial to the optic tract at a depth such that
the dorsal most contact was intraparenchymal, approximately
at the level of the midcommisural plane. Laterally, the target
corresponded to the midpoint of the medial/lateral extent of
the fornix in the coronal plane to maximize the proximity
of the four DBS contacts to the descending column of the
fornix. A burr hole was placed approximately 2.5 cm lateral
to the midline at or just anterior to the coronal suture with
adjustments made so that the lead trajectory would avoid
sulci and deflection from the wall of the frontal horn of the
lateral ventricle. Intraoperative stimulation was performed
at the discretion of the surgeon to evaluate contact position.
After surgery and prior to hospital discharge, an MRI was
conducted to confirm the position of the leads. If necessary,
the implanting surgeon repositioned the leads during the
same hospitalization, followed by a second MRI. A thirdparty-blinded determination of lead position was obtained
by sending the postimplant MRI scan to a neurosurgeon not
involved with surgical implantation of devices for the study,
who subsequently performed stereotactic analysis of the MRI
on a DBS planning station.

Surgical devices and programming
The DBS system used in the study includes the Model 37601
Activa® PC stimulator, Model 3387 Lead, and Model 37085
extension (Medtronic, Inc., Minneapolis, MS, USA). All
implantable devices, external control devices, and accessories (Model 8840 N’Vision® programmer with 8870
Activa applications software and Model 37022 External
neurostimulator) are approved by the FDA for DBS treatment
of Parkinson’s disease and essential tremor. The Activa PC
neurostimulator (Medtronic, Inc.) is a dual-channel device
capable of delivering bilateral stimulation. It contains a
nonrechargeable battery and microelectronic circuitry that
delivers controlled electrical pulses to specifically targeted
brain areas. The device was implanted subcutaneously
just inferior to the clavicle, connected to an extension run
subcutaneously along the head, neck, and shoulder and
connected to the implanted leads. Quadripolar DBS leads
(3387) are made of four thin, insulated coiled wires bundled
with polyurethane insulation. Each lead has four 1.5 mm
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Table 1 ADvance visit schedule

Open Access Journal of Clinical Trials downloaded from https://www.dovepress.com/ by 165.225.104.129 on 24-Sep-2019
For personal use only.

Screen
Procedures
Consent
Review of medication
Medical history
Physical examination
 Electrocardiogram
Preoperative lab testsa
Monitoring lab testsb
Imaging
PET
MRI
Psychiatric consult
CSDD
 YMRS
C-SSRS
Neuropsychological testing
ADAS-cog
CDR
NPI
CVLT
 Digit span
 Digit symbol
Letter fluency
Trail Making Test
BVMT-R
ADCS-ADL23
QOL-AD
ZBI
 Hachinski ischemic scale
DBS device implantation
Randomization
Device program “on”/“off”
Unblinding









Baseline

Implant

Program

1

3

6

9

12

13* 15* 18* 21* 24* 36* 48*


























































































































































































































Months post-DBS device implant



































Notes: *indicates all the devices programmed “on” for open-label follow-up. Phone follow-up will occur at months 27, 30, 33, 39, 42, 45 to assess adverse events or mood,
memory, or personality changes. aCBC, INR, PT, PTT, complete metabolic profile; bTSH, free T3, free T4, prolactin, LH, FSH, free testosterone, ACTH, cortisol, glucose,
complete metabolic profile.
Abbreviations: ACTH, adrenocorticotropic hormone; CBC, complete blood count; ADAS-cog, Alzheimer’s Disease Assessment Scale – cognitive component; ADCSADL23, Alzheimer’s Disease Cooperative Study – Activities of Daily Living; BVMT-R, Brief Visuospatial Memory Test – Revised; CDR, Clinical Dementia Rating Scale; CSDD,
Cornell Scale for Depression and Dementia; C-SSRS, Columbia Suicide Severity Rating Scale; CVLT, California Verbal Learning Test; DBS, deep brain stimulation; FSH,
follicle-stimulating hormone; INR, international normalized ratio; LH, luteinizing hormone; MRI, magnetic resonance imaging; NPI, Neuropsychiatric Inventory; PET, positron
emission tomography; PPT, partial prothrombin time; PT, prothrombin time; QOL-AD, Quality of Life – Alzheimer Disease; TSH, thyroid-stimulating hormone; YMRS, Young
Mania Rating Scale; T3, free triiodothyronine; T4, free thyroxine; ZBI, Zarit Burden Interview.

electrodes at the tip spaced 1.5 mm apart. Stimulation can be
delivered using one electrode or a combination of electrodes.
The N’Vision programmer (8840) is an external component
that noninvasively reviews and adjusts the neurostimulator’s
output parameters.

Randomization, blinding, and DBS-f dosing
The overall study design was a delayed-start trial, in which
all subjects received DBS stimulator implantation and were

Open Access Journal of Clinical Trials 2015:7

randomly allocated to begin DBS-f soon after implantation or
1 year later. Patients were randomized 2 weeks after implantation in a 1:1 allocation to DBS-f “on” or DBS-f “off ”. Random blocks were used to generate randomization for each site,
and the randomization assignment was provided via phone
call to the unblinded technician responsible for programming
the implanted device. Study subjects, the implanting surgeon,
study coordinators, the principal investigator, and follow-up
clinicians responsible for administering questionnaires and

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

67

Dovepress

Open Access Journal of Clinical Trials downloaded from https://www.dovepress.com/ by 165.225.104.129 on 24-Sep-2019
For personal use only.

Holroyd et al

to the DBS-f “on” group, the chosen contact on each side was
set to a voltage of 50% of that eliciting a stimulation-related
event or of 3.5 V, whichever was lower. If a stimulationrelated event was reported with bilateral stimulation, the
voltage was turned down in 0.2 V increments on each lead
until the event was no longer experienced. For each subject
randomized to the DBS-f “off ” group, all leads were set
at 0 V. The programming protocol was completed in full
regardless of DBS-f “on” or DBS-f “off ” randomization
status to prevent unblinding of participants, with the only
difference being the final voltage of the DBS-f electrodes.
The unblinded clinician at each site is responsible for ensuring that the parameters remain consistent throughout the
24-month follow-up unless there are stimulation-associated
side effects or safety concerns. Following the end of the
24-month follow-up visit, programming will be left to the
discretion of the site physician.

Follow-up during the double-blind period
Figure 2 Coronal MRI demonstrating placement of the DBS electrodes anterior and
parallel to the vertical portion of the fornix within the hypothalamus bilaterally.
Abbreviation: DBS, deep brain stimulation.

outcome assessments remain blinded to treatment assignment
until all subjects complete the 12-month visit or until each
subject’s 24-month visit, whichever occurs first. Instances
of emergency unblinding are disclosed to site monitors and
the national primary investigators (CGL and AML). These
procedures are only initiated in cases of compromised subject
welfare and are, whenever possible, reviewed by the national
and site primary investigators and reported to the commercial
sponsor (FNM).
At a follow-up visit 11–17 days following surgery, the
DBS device was programmed according to the randomization
assignment by an unblinded clinician (Table 1). Starting with
the most ventral contact, monopolar stimulation was delivered at a frequency of 130 Hz with a 90-microsecond pulse
width. The initial amplitude was set to 1 V and was increased
incrementally by 1 V every 30–60 seconds to a maximum
until the subject reported experiential phenomena, including
memory-related phenomena or autonomic symptoms (eg,
increased heart rate). Each contact was individually tested,
and the contact on each side that produced an experiential or
autonomic-related event at the lowest voltage was chosen as
the therapeutic contact. If no experiential phenomena were
produced with stimulation, the contact that had the highest
threshold for autonomic adverse effects was chosen. This
was usually contact 2 or 3, the two most superior of the four
contacts on the DBS electrodes. For each subject randomized
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Follow-up visits are scheduled for 1, 3, 6, 9, and 12
months after implantation. These visits include a physical
examination, psychiatric consultation, neuropsychological testing, blood tests (6, 12 months), PET scans (1, 6,
12 months), and brain MRI (12 months). All subjects,
including patients randomized to DBS-f “off ”, have the
implanted device programmed “on” after the 12-month
visit for a subsequent open-label treatment phase. Openlabel follow-up visits are scheduled for 13, 15, 18, 21, 24,
36, and 48 months after implantation. These visits consist
of safety monitoring, clinical updates, physical examination, psychiatric consultation, and/or neuropsychological
testing (18, 24 months). There will be additional phone
follow-ups at months 27, 30, 33, 39, 42, and 45 to assess
any adverse events (AEs) or changes in cognition or personality. Subjects will exit the study at the conclusion of
their 48-month visit (Table 1).

PET and MRI
MRI and PET protocols were implemented based on the AD
Neuroimaging Initiative (ADNI) protocols that have been
used extensively to measure longitudinal changes in gray
matter volumes (MRI) and cerebral glucose metabolism
across different MRI and PET scanners and study sites.38,39
PET scans with the radiotracer [18F]-2-deoxy-2-fluoro-dglucose ([18F]-FDG) to measure regional cerebral glucose
metabolism are acquired preoperatively and at 1, 6, and
12 months. PET scans are performed on a PET/CT scanner
at each site using a uniform protocol and postprocessing

Open Access Journal of Clinical Trials 2015:7
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methods designed to obtain comparable measurements of
cerebral glucose metabolism across scanners/sites.40 During
radiotracer uptake, subjects are maintained in a quiet, dimly
lit room, with eyes open and ears unoccluded. Thirty minutes after a 5 mCi ±10% radiotracer injection, patients are
positioned in the scanner, and a 20-minute emission scan
is obtained, followed by a transmission scan. The second,
10-minute frame of the emission scan (40 minutes after
[18F]-FDG administration) is used for quantitative analysis.
The MRI protocol was designed to detect focal pathology
(eg, tumors or strokes) and for MRI-PET registration to
define regions of interest. The MRI scans were performed
prior to the first PET scan, 1–2 days postoperatively, and are
repeated at 12 months. MRI scans are acquired on 1.5 T scanners at each site. The sequences were implemented from the
ADNI protocols that were developed for each MRI scanner
to obtain comparable quantitative measurements, including
gray matter volumes.38,39 The MRI sequences include 3-plane
localizer, volumetric sequence (magnetization-prepared
rapid gradient-echo or spoiled gradient recalled echo), T2
sequences for electrode localization (postoperative scan
only), fast spin-echo inversion recovery (FSE-IR), DTI
(when available), and resting-state functional MRI (when
available).

Safety monitoring
An independent Clinical Events Committee (CEC) consisting of a multidisciplinary team of physicians from geriatrics,
neurology, and neurosurgery who are not investigators in
the study was created. The CEC conducts reviews of all
AEs reported for study subjects. Each AE is adjudicated for
its relatedness to the study, surgical procedure, implantable
pulse generator, leads (electrodes), and programming. AEs
are categorized as general medical, psychiatric, surgical, or
programming in nature. In addition, adjudications are made
regarding whether an event is a serious AE or an unanticipated adverse device effect. Psychiatric AEs are assessed at
each follow-up visit using measures such as the C-SSRS,36
CSDD,37 and YMRS.35
A separate independent Data Safety and Monitoring
Board (DSMB) of one practicing neurosurgeon, two neurologists and/or psychiatrists, and one biostatistician not
connected to the sponsor or participating investigators was
established. The DSMB reviews CEC-adjudicated AEs,
occurrences of serious AEs and unanticipated adverse device
effects, as well as safety and efficacy trends and makes
recommendations regarding the continuation, suspension,
or termination of the study. Following each review by the
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DSMB, a summary of results is sent to the FDA and filed
with all overseeing institutional review boards.

Outcome measures and analytic plan
Safety outcome assessment

Doctors and clinical staff at local sites are in regular contact
with participants and study partners to monitor for AEs, as
described earlier. As soon as an AE is detected, the local
team obtains as much clinical information as possible and
rapidly reports to the study principal investigator, the medical monitor, and the coordinating center. The coordinating
center, working as a team, then reviews, requests additional
information, notifies other sites, and notifies DSMB, institutional review boards, and FDA as spelled out in study
procedures. AEs will be presented as a measure of the safety
of DBS-f surgery and treatment for mild AD.

Clinical outcome assessment
One primary goal of this study is to examine the acute and
long-term safety of DBS-f for mild AD. Acute safety is
assessed by the rate of serious device- or procedure-related
AEs from the date of implant through the date of randomization as well as serious procedure-related events through
30 days postimplant. Long-term safety is assessed by the rate
of serious therapy (programming) related AEs from the date
of randomization through the date of the 12-month visit.
The second goal of this study is to preliminarily examine
the efficacy of DBS-f for mild AD. The two primary outcomes
are change from baseline in the ADAS-cog and CDR sum of
boxes (CDR-SB) scores. The ADAS-cog is one of the more
commonly used measures to assess cognitive symptoms
associated with AD in clinical trials. The ADAS-cog is able
to differentiate individuals with nonimpaired cognition
from those with impaired cognition and has demonstrated
reliability in assessing the extent of cognitive impairment in
individuals.41 The standard ADAS-cog consists of 11 subscales designed to assess memory, language, and praxis, and
scoring is based on the number of errors made on each item,
with a higher score indicating greater impairment. Previous
clinical trials have indicated that a four-point change on the
ADAS-cog total score is suggestive of a clinically important
difference.42,43 However, systematic analysis of double-blind
placebo-controlled trials of cholinesterase inhibitors demonstrated an average -2.7 improvement at 6 months and 1
year.44 The CDR was developed for the evaluation of staging
severity of dementia.45 The CDR characterizes cognitive
and functional performance by assessing the subject in six
domains including memory, orientation, and problem solving.
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The CDR has consistently demonstrated good reliability46,47
and has been validated against neuropathological findings.48,49
A global CDR score is computed via an algorithm based
on the input of the ratings of the six domains and is useful
for characterizing and tracking a subject’s level of impairment and stage of dementia severity,45 with values between
0 (normal) and 3 (severe dementia). The CDR-SB score is
obtained by summing each of the six domain ratings. CDRSB scores range from 0 to 18, with higher scores reflecting
more severe impairment.46
Secondary outcomes include change from baseline to
12 months in scores on other cognitive tests: California Verbal
Learning Test, second edition (CVLT-II50); Verbal Fluency;51
Brief Visuospatial Memory Test – revised version;52 and Trail
Making Test.53 Other measures include Quality of Life – AD,
which is a rating of the patient’s quality of life both from the
patient and the caregiver,54 AD Cooperative Study – Activities of Daily Living Inventory, Zarit Burden Interview to
assess caregiver distress,55 and NPI to assess the presence
of psychiatric symptoms and behaviors.33

Neuroimaging outcome assessment
The primary neuroimaging outcome measure is a regional
change in glucose metabolism from baseline to 12 months,
measured by PET. Previous research using PET measures
of cerebral glucose metabolism has identified a specific pattern in AD of hypometabolism in the parietal and temporal
heteromodal association cortices.56 This pattern has been
found in over 85% of pathologically confirmed AD cases56
and has been correlated with dementia severity.56 FDG-PET
is sensitive to AD clinical progression and to effects of pharmacotherapy, including DBS.15,26,57–59
A secondary imaging outcome is bilateral hippocampal
volume measured using volumetric methods, decreases in
which have been correlated with the progression of AD.21,22 An
additional imaging tool of interest is fornix integrity measured
with DTI for which the fornix is manually drawn (with high
reliability) as a region of interest. However, we do not plan
to use DTI obtained after implantation analytically due to
concerns about interference by the implanted electrodes.

For the acute safety end point, rate and 95% confidence
interval will be presented. For long-term safety end points,
rate and 95% confidence interval will be compared according
to randomization group. Other data summaries will include
a detailed summary and rate estimation of all serious AEs,
as well as Kaplan–Meier estimates of the cumulative rates
over time.
For the two clinical efficacy outcomes of particular
interest (ADAS-cog score and CDR score), all analyses
will follow intent-to-treat (ITT) or modified-ITT principles.
The mean change from baseline (preimplant) to 12 months
postimplant will be calculated in each group. Differences
between randomized groups in mean change on each of
these primary outcomes will be calculated, along with corresponding two-sided 95% confidence intervals. In addition,
within group improvements will be assessed relative to a null
change of zero. Additional analyses will include assessments
of change over time in mixed model regression estimations
with repeated measurements. Site will be used as a covariate
in this model.
In addition to ADAS-cog-13 total score, this method will
also be used to examine derived Word Recall Total score,
Word Recognition scores, and the subset of five ADAS-cog
items shown to be most sensitive to memantine. The subsetting methodology described by Ihl et al60 will be applied to
this data set to assess the relative strength of treatment effect
across other subtests of the ADAS-cog. Further analyses will
be conducted to determine the impact of baseline ADAS-cog
scores on outcome (ie, to assess whether the treatment effect
diminishes in the more advanced population), including
mixed model regression analyses with baseline ADAS-cog
score as a predictor, and fit with an interaction term. Withingroup outcomes, by baseline ADAS-cog score also will be
summarized. CDR analyses will include global score, SB,
and memory domain score. In addition we will analyze the
CDR-SB score relative to the overall severity classification
from the ADAS-cog to determine the agreement of categorization of mild symptom severity at baseline with how the
scores change together over time.

Neuroimaging measure analytic plan
Clinical measure analytic plan
All analyses will be conducted according to the prespecified
statistical analysis plan for the study. Descriptive statistics compare treatment group on baseline demographics.
Categorical variables are analyzed using frequency, incidence, and event rate. For continuous variables, analyses
include mean, median, standard deviation, and range.
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The end point is the mean, per-subject, percent glucose metabolism change in prespecified regions of interest, including the
subdivisions of the temporal and parietal association cortex and
the hippocampus. The primary analysis will be conducted on
an ITT basis. The percent improvement for each subject will
be determined by subtracting the baseline value for glucose
metabolism in each region of interest (ROI-BL) from the
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12-month glucose metabolism (ROI-12) and dividing the result
by ROI-BL ([ROI-12 − ROI-BL]/ROI-BL). This quantity will
be averaged across all subjects, and mean improvement will be
compared across randomization groups in a two-sample t-test
evaluated at the 0.05 significance level. Supportive analyses
will only evaluate those subjects with complete data and/or
those who are compliant with the protocol.
Exploratory analyses will be conducted to evaluate the
relationship between changes in regional glucose metabolism
and changes in clinical outcomes (eg, ADAS-cog, CVLT, etc).
Exploratory analyses will be performed to identify baseline
structural and functional neuroimaging predictors of DBS
clinical response. These analyses may include, but not be limited to, regional glucose metabolism, hippocampal volumes,
and regional white matter functional integrity (DTI). These
analyses will fit multivariate linear regression models, with the
candidate predictor and randomization assignment, and their
interaction as independent variables, and clinical outcome (eg,
ADAS-cog-11, CDR-SB, CVLT) as the dependent variable.
Covariates with apparent effect on outcome will then be fit
in a multivariate regression model with stepwise selection
procedure using significance level of 0.10 as a cutoff.

Power estimation
The power to detect a treatment effect depends on the size of
the effect, sample size, and the configuration of the withinperson variance–covariance matrix. For the ADAS-cog, we
conducted a power simulation using ADNI data. Assuming
a mixed effects model with random intercept and slope, no
missing data, variance of intercept =(4.68)2, variance of
slope =(0.37)2, correlation between random intercept and
random slope of 0 (model with unstructured covariance
failed to converge), variance of residuals =(5.87)2, time
vector = c (0,3,6,9,12), there is 84% power to detect a difference in change scores of 7.53 points with 42 subjects,
which translates to a difference in slopes of 0.63. We will
have 80% power to detect a difference in slope of 0.588
points/month or 7.06 points/year. Using the same method,
the power to detect a difference in a change of score of 4.0
points (a typical effect size) was calculated to be 36%, which
translates to a difference in slopes of 0.33.
Statistical power for the neuroimaging hypothesis listed
previously was estimated using PASS 2008 software under
a two-sided, two-sample t-test and the assumption of 40 randomized subjects in a 1:1 allocation. Assuming a significance
level (α) of 5%, mean improvement (DBS) of 10%, standard
deviation (DBS and control) of 12%, and mean improvement
(control) of 0.0%, a total of 40 randomized subjects provides
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at least 80% power to statistically evaluate the end point of
glucose metabolism as specified earlier.

Results
Characterization of the baseline
study population
Following recruitment, 85 potential subjects across the
seven study sites signed the initial consent and participated
in a screening visit. Forty-eight (56.5%) met all inclusion
and exclusion criteria at screening and were approved by
ERC reviewers to proceed in the trial. Forty-two of these
48 patients (49.4% of consenting potential subjects) met all
criteria following the baseline visit, signed a second consent form, and underwent DBS-f device implantation. The
six patients who were cleared at screening but did not proceed
to implant did so for two reasons: two declined to proceed
and did not sign consent for baseline testing, and four failed
to meet inclusion/exclusion criteria when ADAS-cog was
repeated at baseline, with scores out of range.
We compared (Table 2) consenting subjects who were
screened and successfully implanted (N=42) to those who
were screened but not implanted with a DBS device (N=43).
We saw no difference between these groups in demographic
information (age, sex, and elapsed time since initial AD diagnosis) gathered at screening. We observed significantly lower
(ie, better) ADAS-cog-11 (17.5±3.6 vs 21.1±9.8, P=0.03) and
CDR global scores (67% vs 38%, with a score of 0.5, P=0.05)
in subjects who were implanted. This is explained by the inclusion and exclusion criteria designed to limit participation to
subjects with very mild AD. Approximately 40% of patients
who failed screening did so because symptom severity was too
high. No significant difference was found in CDR-SB score,
Hachinski ischemic scale score, or psychiatric assessment
measures, including the NPI, C-SSRS, CSDD, or the YMRS
in implanted compared to not implanted patients (Table 2).
Table 2 summarizes the scores of implanted subjects on
additional cognitive and psychiatric tests from the baseline
visit. In addition to inclusion criteria measures such as the
CDR, scores on the CVLT-II, a verbal memory measure, were
similar to published scores of individuals with MCI who later
progressed to AD.61 Note that these additional scores include
all 48 subjects who were assessed at baseline, not only the
42 who were implanted.

Reliability of primary outcome measures
We examined test–retest reliability of the main outcome
measures by comparing score stability between the screening
and baseline visits for the 42 implanted subjects. There was
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Table 2 Demographics and screening measures by implantation
status
Patient
characteristic

Screened and
implanted
(n=42)

Screened and
not implanted
(n=43)

P-value*

Age (years)
Sex (male)
Elapsed time since initial
diagnosis of AD (years)
ADAS-cog-11 score
ADAS-cog-13 score
CDR global score: 0.5
CDR global score: 1
CDR global score: 2
CDR sum of boxes
score
NPI total score
Hachinski ischemic
scale score
C-SSRS score
CSDD score
YMRS score
GMHR scorea
CVLT-II – sum of first
five recall trials Aa
CVLT-II – short delay
free recall Aa
CVLT-II – short delay
free recall Ca
CVLT-II – long delay
free recall Aa
ADCS-ADL23 scorea

68.2±7.8
55%
2.5±1.9

66.8±7.4
47%
1.6±1.4

0.41
0.45
0.06

17.5±3.6
28.9±5.2
67%
33%

0.03
0.08
0.05

3.9±1.6

21.1±9.8
32.3±11.4
38%
57%
5%
4.5±2.3

2.8±2.8
0.5±0.6

4.7±7.1
0.4±0.5

0.12
0.34

0.2±0.8
1.8±2.1
0.18±0.58
3.9±0.3
20.3±9.1

0.3±0.7
2.2±3.6
0.16±0.50
NA
NA

0.74
0.54
0.89

1.9±1.9

NA

3.6±2.5

NA

1.5±2.2

NA

69.5±6.0

NA

0.30

Notes: *P-values for continuous measure calculated by t-tests; P-values for discrete
measures calculated by chi-squared tests; adata gathered at baseline visit.
Abbreviations: AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease
Assessment Scale – cognitive component; ADCS-ADL23, Alzheimer’s Disease
Cooperative Study – Activities of Daily Living; CDR, Clinical Dementia Rating
Scale; NPI, Neuropsychiatric Inventory; CSDD, Cornell Scale for Depression and
Dementia; C-SSRS, Columbia Suicide Severity Rating Scale; CVLT-II, California
Verbal Learning Test, second edition; GMHR, General Medical Health Rating score;
NA, not applicable; YMRS, Young Mania Rating Scale.

a moderate correlation between screening and baseline visit
scores for ADAS-cog-11 and a high correlation for ADAScog-13, CDR global score, CDR-SB, and NPI (Table 3). The
stability in scores seen within subjects across initial visits
suggests that our primary clinical outcome measures are
reliable for the population in this study and can be used to
measure disease progression over time in this trial.

Discussion
ADvance is the first multicenter, randomized, double-blind
controlled clinical trial evaluating the efficacy of DBS-f
for mild AD. This paper outlines the methods used in the
ADvance trial and characterizes the study population.
Subjects demonstrate cognitive test scores indicative of mild
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Table 3 Correlation* between screening and baseline value
Measure

N

Pearson’s
correlation

Intraclass
correlation

ADAS-cog-11 score
ADAS-cog-13 score
CDR global score
CDR sum of boxes score
NPI total score

42
42
42
42
42

0.42
0.54

0.41
0.51

0.68
0.59

0.69
0.60

Kappa

0.68

Notes: *The kappa statistic is reported for the CDR global score; the Pearson and
intraclass correlation coefficients are reported for all the other measures.
Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment Scale – cognitive
component; CDR, Clinical Dementia Rating scale; NPI, Neuropsychiatric Inventory.

AD, and implanted participants differ from consenting nonimplanted participants only on average ADAS-cog-11 and
CDR global scores. Furthermore, we confirm the reliability
of the primary outcome measures used in the ADvance study
population by demonstrating consistency across two visits.
ADvance joins three smaller DBS studies conducted in
AD patients published thus far62 and builds on data from
approximately 25 animal studies. 23,24,28,63 ADvance was
designed based on an open-label Phase I study of DBS-f
conducted in six patients with mild AD, as previously
discussed. Interestingly, patients with less severe prestimulation cognitive dysfunction and less severe metabolic deficits
were more likely to benefit from DBS-f in this trial.15 This
study provided the basis for the inclusion criteria used in
ADvance, which focus on selection of participants with very
mild AD. Implanted participants were younger, more likely
to be male, and had lower baseline ADAS-cog-11 scores
than the mean scores in recently reported Phase III trials of
amyloid-lowering agents in AD.64–66 Mean ADAS-cog-11 was
17.5 for implanted ADvance participants, and ranged from
19 to 23 in recent Phase III trials. Thus, our participants were
younger and less impaired than those in these Phase III trials,
but the differences were relatively small.
Fontaine et al67 recruited 110 patients with Alzheimer
dementia or MCI to be screened for a study assessing
DBS for cognitive decline, and one subject met criteria,
consented, and continued on to implantation. In the current
study, 42 of 85 screened subjects consented and underwent
implantation. One possible explanation for this difference
may be that the Fontaine et al67 study required subjects
to have received a DSM-IV AD diagnosis within 2 years
and have a mini–mental state examination score between
20 and 24, which was not required in the ADvance study.
It also is possible that the 1-year open-label follow-up
phase used in ADvance may have contributed to improved
participation.
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Another study in 2014 examined open-label DBS targeting
the nucleus basalis of Meynert in six patients meeting criteria
for mild-to-moderate AD. Although ADAS-cog scores worsened by an average of 3 points after 1 year of stimulation, the
authors noted that this was less than the average 6- to 7-point
worsening seen in prior reports of patients with AD. Further,
global increases in metabolism in amygdalohippocampal and
temporal regions were seen in three out of the four patients who
underwent PET scans of cerebral glucose metabolism.68
Taken in the context of prior research, ADvance is a novel,
important step in studying DBS-f as a treatment for mild
AD. The subject pool is much larger than prior studies and
involves 1 year of double-blind, controlled cognitive testing
and neuroimaging. The 1-year duration of the controlled
comparison increases the likelihood of identifying significant
differences between the stimulated (treatment arm) and nonstimulated (control arm) cohorts in this slowly progressive
disorder. The 1-year blinded, controlled phase of the study is
followed by up to 3 years of continued open-label follow-up
with all patients being stimulated, which affords systematic pre- and postassessment of outcomes in about half the
participants, and 2 years of additional follow-up. While the
primary objective of the study is to evaluate safety, the larger
subject population and controlled design affords preliminary
testing of the efficacy of DBS-f in delaying cognitive decline
and improving cortical glucose metabolism.
The ADvance methodology outlined here is strengthened
by recruitment from seven sites with experienced investigators and rigorous subject selection by an independent ERC.
The primary clinical outcome measures are standardized and
validated and have been widely used so that the results of the
current study can be evaluated in comparison to studies that
tested other symptomatic treatments such as cholinesterase
inhibitors.69 The neuroimaging outcome measures, especially
cerebral glucose metabolism, have also been well studied in
AD56,57,70,71 and enable us to examine changes in brain function throughout the trial. Limitations of ADvance include
limited sample size. Although larger than prior DBS studies,
there are only 21 patients in each of the masked treatment
groups. The goal is that the results of ADvance will inform a
larger-scale clinical trial focused primarily on efficacy, rather
than on safety, of DBS-f as a treatment for mild AD.
Research elucidating the neurobiological mechanism
of DBS treatment for neurodegenerative diseases such as
AD remains limited. While we hypothesize that this treatment works by stimulation of fornix–hippocampal–cortical
circuits, and potentially even promotes neurogenesis in the
hippocampus, this remains unproven. The memory circuits
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we are examining may be undergoing degeneration at
varying rates in individual study participants, limiting the
effectiveness of DBS-f to slow cognitive decline and our
ability to examine the efficacy of DBS-f within our study
population.
In summary, the ADvance trial was successful in enrolling appropriate patients for a novel application of DBS, and
we believe several unique design aspects outlined here could
be considered in future clinical trials of DBS targeting AD
and other cognitive disorders.

Acknowledgments
This research is supported by a grant from the National Institute on Aging, R01AG042165, and a vendor grant received
from Functional Neuromodulation Ltd, the sponsor of the
ADvance study.
The ADvance study team includes Todd Langevin,
Lisa Fosdick, Kristen Drake, Donald E Reymers, Robyn
Moxon, Dan O’Connell, Vince Owens, Cara Pendergrass,
Susan Klees, Steven D Targum, and the seven participating
clinical trial sites.
Chair’s office at Johns Hopkins University and University
of Toronto: Constantine G Lyketsos, MD, MHS, coprincipal
investigator; Elizabeth Plank Althouse, professor and chair
of psychiatry at Johns Hopkins Bayview; Andres M Lozano,
MD, PhD, FRCSC, FACS, co-principal investigator, professor, and Chair of Neurosurgery, Tasker Chair of Functional
Neurosurgery; Gwenn Smith, PhD, imaging core director,
professor of psychiatry and behavioral sciences, Johns Hopkins University; Cynthia Munro, PhD, neuropsychologist,
associate professor of psychiatry and behavioral sciences,
Johns Hopkins University; Esther Oh, MD, medical monitor, assistant professor of geriatric medicine, Johns Hopkins
University; Jeannie Sheppard Leoutsakos, PhD, data core
leader, assistant professor of psychiatry and behavioral sciences, Johns Hopkins University.

Clinical trial sites
Johns Hopkins University School of Medicine, Baltimore,
MD: Paul Rosenberg, MD, associate professor, associate
director, Memory and Alzheimer’s Treatment Center; William
S Anderson, MD, associate professor of neurosurgery.
University of Toronto/Toronto Western Hospital: Andres
M Lozano, MD, PhD, FRCSC, FACS, professor of neurosurgery, Tasker Chair of Functional Neurosurgery; David F TangWai, MDCM FRCPC, associate professor of neurology.
Banner Alzheimer’s Institute, Phoenix: Anna Burke, MD,
geriatric psychiatrist, dementia specialist; Francisco A Ponce,

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

73

Dovepress

Open Access Journal of Clinical Trials downloaded from https://www.dovepress.com/ by 165.225.104.129 on 24-Sep-2019
For personal use only.

Holroyd et al

MD, associate professor of neurosurgery, director of Barrow
Center for Neuromodulation.
Banner Sun Health Research Institute, Sun City:
M arwan Sabbagh, MD, director, Banner Sun Health
Research I nstitute; Francisco A Ponce, MD, associate
professor of neurosurgery, director of Barrow Center for
Neuromodulation.
Brown University, Rhode Island Hospital, Butler
Hospital: Stephen Salloway, MD/MS, professor of neurology,
director of neurology and memory and aging program; Rees
Cosgrove, MD/PhD, chair of neurosurgery; Wael Asaad, MD/
PhD, assistant professor of neurosurgery.
University of Florida – Gainesville: Michael S Okun,
MD, professor of neurology, codirector of the Center
for Movement Disorders and Neurorestoration; Kelly D
Foote, MD, professor of neurosurgery, codirector of the
Center for Movement Disorders and Neurorestoration.
University of Pennsylvania: David A Wolk, MD, associate professor of neurology, assistant director of Penn
Memory Center; Gordon Baltuch, MD/PhD, professor of
neurosurgery, director of the Center for Functional and
Neurorestorative Neurosurgery.

Disclosure
Steven D Targum: Has received consultation fees, retainers,
or vendor grants from the following: Acadia Pharmaceuticals,
Acumen, Alcobra, Alkermes Inc., AstraZeneca, BioMarin,
BrainCells Inc., CeNeRx Pharmaceuticals, Clintara, LLC,
Civitas, Eli Lilly and Company, EnVivo (Forum) Pharmaceuticals, Functional Neuromodulation Inc., Johnson & Johnson
PRD, Intracellular Therapies Inc., Methylation Sciences Inc.,
Mitsubishi Tanabe, Neurophage, Nupathe, Pfizer Inc., Prana
Biotechnology Ltd, ReViva Pharmaceuticals, Roche Labs,
Sophiris, Sunovion, Targacept, Theravance, Transcept.
Kristen Drake: Has no conflicts of interests other than
being an employee of Functional Neuromodulation Inc.
J Cara Pendergrass: Has no conflicts of interests other
than being an employee of Clintara LLC.
Gwenn S Smith: Has received grant support as follows:
NIH RO1 MH086881, AG038893, AG041633.
Paul B Rosenberg: Has received consultation fees from
Pfizer, Janssen, Global Exchange for Alzheimer’s Research,
Abbvie, Lundbeck; research grant support from Lilly, Merck,
Pfizer, Elan, Janssen, Functional Neuromodulation Inc.,
American Federation for Aging Research, and the National
Institute on Aging.
Michael S Okun: Has served as a consultant for the
National Parkinson Foundation and has received research

74

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

grants from NIH, NPF, the Michael J Fox Foundation, the
Parkinson Alliance, Smallwood Foundation, the BachmannStrauss Foundation, the Tourette Syndrome Association,
and the UF Foundation. Dr Okun has previously received
honoraria, but has received no support from industry in
more than 60 months. Dr Okun has received royalties for
publications with Demos, Manson, Amazon, Smashwords,
Books$Patients, and Cambridge (movement disorders
books). Dr Okun is an associate editor for the New England
Journal of Medicine Journal Watch Neurology. Dr Okun
has participated in CME and educational activities on
movement disorders (in the last 36 months) sponsored by
PeerView, Prime, Quantia, Henry Stewart, and by Vanderbilt
University. The institution and not Dr Okun receives grants
from Medtronic, Abbvie, and ANS/St Jude, and the PI has no
financial interest in these grants. Dr Okun has participated
as a site PI and/or co-I for several NIH-, foundation-, and
industry-sponsored trials over the years but has not received
honoraria.
Marwan Sabbagh: Has received grants, honoraria, travel
support from the following: Amarantus, Avanir, Avid, BiogenIdec, BSHRI: DART, Eli Lilly and Company, Functional
Neuromodulation Inc., Genentech, Merck, Neuronix,
Navidea, Piramal, Roche, Takeda; has received royalties from
Tenspeed/Random House.
Andres M Lozano: Is cofounder of Functional Neuromodulation and has received consultation fees from the
following: Aleva, Boston Scientific, Brainstorm, Codman,
Elekta, Eli Lilly and Company, Insightec, Michael J Fox
Foundation, Medtronic, Neuronova, Neurophage, Neuropace,
St Jude, Schering.
Constantine G Lyketsos: Has received grant support from
the following: AstraZeneca, Associated Jewish Federation of
Baltimore, Bristol-Myers, Forest, GlaxoSmithKline, Eisai,
Elan, Functional Neuromodulation, Lilly, National Football
League, NIMH, NIA, Novartis, Ortho-McNeil, Pfizer Inc.,
Weinberg Foundation; has received consulting fees, honoraria, or travel support from the following: Abbvie, Adlyfe,
AstraZeneca, Avanir, Bristol-Myers, Eisai, Elan, Eli Lilly
and Company, Forest, Genentech, GlaxoSmithKline, Health
Monitor, Janssen, Lundbeck, Merz, NFL Players Association,
NFL Benefits Office, Novartis, Orion, Pfizer Inc., Supernus,
Takeda, Wyeth, Zinfandel.
The authors report no other conflicts of interest in this work.

References

1. Lanctôt KL, Rajaram RD, Herrmann N. Therapy for Alzheimer’s disease: how effective are current treatments? Ther Adv Neurol Disord.
2009;2(3):163–180.

Open Access Journal of Clinical Trials 2015:7

Open Access Journal of Clinical Trials downloaded from https://www.dovepress.com/ by 165.225.104.129 on 24-Sep-2019
For personal use only.

Dovepress
2. Latest Facts and Figures Report. 2014. Accessed October 1, 2014.
3. Wimo A, Prince M. World Alzheimer Report 2010: The Global Economic
Impact of Dementia. London, United Kingdom: Alzheimer’s Disease
International (ADI); 2010.
4. Aisen PS, Saumier D, Briand R, et al. A phase II study targeting
amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
Neurology. 2006;67(10):1757–1763.
5. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition,
activities of daily living, behaviour, and global function in patients with
mild-to-moderate Alzheimer’s disease: a randomised, double-blind,
placebo-controlled study. Lancet. 2008;372(9634):207–215.
6. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending
dose trial of bapineuzumab in mild to moderate Alzheimer disease.
Neurology. 2009;73(24):2061–2070.
7. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer
disease: a randomized controlled trial. JAMA. 2009;302(23): 2557–2564.
8. Andrews-Hanna JR, Snyder AZ, Vincent JL, et al. Disruption of
large-scale brain systems in advanced aging. Neuron. 2007;56(5):
924–935.
9. Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by
intrinsic functional connectivity: mapping, assessment of stability, and
relation to Alzheimer’s disease. J Neurosci. 2009;29(6):1860–1873.
10. Davis KD, Kiss ZH, Luo L, Tasker RR, Lozano AM, Dostrovsky JO.
Phantom sensations generated by thalamic microstimulation. Nature.
1998;391(6665):385–387.
11. Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain
stimulation of the subthalamic nucleus or the pars interna of the globus
pallidus in Parkinson’s disease. N Engl J Med. 2001;345(13): 956–963.
12. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation
vs best medical therapy for patients with advanced Parkinson disease:
a randomized controlled trial. JAMA. 2009;301(1):63–73.
13. Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC,
Kennedy SH. Subcallosal cingulate gyrus deep brain stimulation for
treatment-resistant depression. Biol Psychiatry. 2008;64(6):461–467.
14. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for
treatment-resistant depression. Neuron. 2005;45(5):651–660.
15. Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of
deep brain stimulation of memory circuits in Alzheimer’s disease. Ann
Neurol. 2010;68(4):521–534.
16. Hopper MW, Vogel FS. The limbic system in Alzheimer’s disease.
A neuropathologic investigation. Am J Pathol. 1976;85(1):1–20.
17. Yasmin H, Aoki S, Abe O, et al. Tract-specific analysis of white matter
pathways in healthy subjects: a pilot study using diffusion tensor MRI.
Neuroradiology. 2009;51(12):831–840.
18. Rudebeck SR, Scholz J, Millington R, Rohenkohl G, Johansen-Berg H,
Lee AC. Fornix microstructure correlates with recollection but not
familiarity memory. J Neurosci. 2009;29(47):14987–14992.
19. Gaffan EA, Gaffan D, Hodges JR. Amnesia following damage to
the left fornix and to other sites. A comparative study. Brain. 1991;
114(Pt 3):1297–1313.
20. Oishi K, Mielke MM, Albert M, Lyketsos CG, Mori S. The fornix
sign: a potential sign for Alzheimer’s disease based on diffusion tensor
imaging. J Neuroimaging. 2012;22(4):365–374.
21. Fletcher E, Raman M, Huebner P, et al. Loss of fornix white matter
volume as a predictor of cognitive impairment in cognitively normal
elderly individuals. JAMA Neurol. 2013;70(11):1389–1395.
22. Mielke MM, Kozauer NA, Chan KC, et al. Regionally-specific diffusion
tensor imaging in mild cognitive impairment and Alzheimer’s disease.
Neuroimage. 2009;46(1):47–55.
23. Toda H, Hamani C, Fawcett AP, Hutchison WD, Lozano AM. The
regulation of adult rodent hippocampal neurogenesis by deep brain
stimulation. J Neurosurg. 2008;108(1):132–138.
24. Hamani C, Stone SS, Garten A, Lozano AM, Winocur G. Memory
rescue and enhanced neurogenesis following electrical stimulation of
the anterior thalamus in rats treated with corticosterone. Exp Neurol.
2011;232(1):100–104.

Open Access Journal of Clinical Trials 2015:7

Fornix DBS for mild AD: methods and baseline population description
25. Smith GS, Laxton AW, Tang-Wai DF, et al. Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch
Neurol. 2012;69(9):1141–1148.
26. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM.
Longitudinal PET evaluation of cerebral metabolic decline in dementia:
a potential outcome measure in Alzheimer’s disease treatment studies.
Am J Psychiatry. 2002;159(5):738–745.
27. Damoiseaux JS, Prater KE, Miller BL, Greicius MD. Functional
connectivity tracks clinical deterioration in Alzheimer’s disease.
Neurobiol Aging. 2012;33(4):828. e819–e830.
28. Hamani C, McAndrews MP, Cohn M, et al. Memory enhancement
induced by hypothalamic/fornix deep brain stimulation. Ann Neurol.
2008;63(1):119–123.
29. Hyman BT, Phelps CH, Beach TG, et al. National Institute on AgingAlzheimer’s Association guidelines for the neuropathologic assessment
of Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1–13.
30. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull.
1988;24(4):637–639.
31. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s
disease. Am J Psychiatry. 1984;141(11):1356–1364.
32. Lyketsos CG, Galik E, Steele C, et al. The General Medical Health
Rating: a bedside global rating of medical comorbidity in patients with
dementia. J Am Geriatr Soc. 1999;47(4):487–491.
33. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA,
Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment
of psychopathology in dementia. Neurology. 1994;44(12): 2308–2314.
34. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol.
1980;7(5):486–488.
35. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for
mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:
429–435.
36. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity
Rating Scale: initial validity and internal consistency findings from
three multisite studies with adolescents and adults. Am J Psychiatry.
2011;168(12):1266–1277.
37. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale
for depression in dementia. Biol Psychiatry. 1988;23(3):271–284.
38. Jack CR, Bernstein MA, Fox NC, et al. The Alzheimer’s Disease
Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging.
2008;27(4):685–691.
39. Jack CR, Bernstein MA, Borowski BJ, et al. Update on the magnetic
resonance imaging core of the Alzheimer’s disease neuroimaging
initiative. Alzheimers Dement. 2010;6(3):212–220.
40. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer’s Disease
Neuroimaging Initiative positron emission tomography core. Alzheimers
Dement. 2010;6(3):221–229.
41. Benge JF, Balsis S, Geraci L, Massman PJ, Doody RS. How well do the
ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer’s
disease? Dement Geriatr Cogn Disord. 2009;28(1):63–69.
42. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or
naproxen vs placebo on Alzheimer disease progression: a randomized
controlled trial. JAMA. 2003;289(21):2819–2826.
43. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of
outcome in retrieved dropout patients in a rivastigmine vs placebo,
26-week, Alzheimer disease trial. Arch Neurol. 2003;60(6):843–848.
44. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane
Database Syst Rev. 2006(1):CD005593.
45. Morris JC. The Clinical Dementia Rating (CDR): current version and
scoring rules. Neurology. 1993;43(11):2412–2414.
46. O’Bryant SE, Waring SC, Cullum CM, et al. Staging dementia
using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas
Alzheimer’s research consortium study. Arch Neurol. 2008;65(8):
1091–1095.
47. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and
staging measure for dementia of the Alzheimer type. Int Psychogeriatr.
1997;9(Suppl 1):173–176; discussion 177–178.

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

75

Dovepress

Open Access Journal of Clinical Trials downloaded from https://www.dovepress.com/ by 165.225.104.129 on 24-Sep-2019
For personal use only.

Holroyd et al
48. Morris JC, Storandt M, McKeel DW, et al. Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology. 1996;46(3):
707–719.
49. Berg L, McKeel DW, Miller JP, Baty J, Morris JC. Neuropathological
indexes of Alzheimer’s disease in demented and nondemented persons
aged 80 years and older. Arch Neurol. 1993;50(4):349–358.
50. Delis DC, Kramer JH, Kaplan E, Ober BA, [Inventors]. California
Verbal Learning Test – Second Edition. 2000.
51. Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage.
Neuropsychologia. 1967;5:135–140.
52. Benedict R. Brief Visuospatial Learning Test-Revised, Professional
Manual. Lutz, FL: Psychological Assessment Resources; 1997.
53. Reitan RM. Validity of the Trail Making test as an indicator of organic
brain damage. Perceptual Motor Skills. 1958;8:271–276.
54. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality
of life in older adults with cognitive impairment. Psychosom Med.
2002;64(3):510–519.
55. Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F. Review
of Alzheimer’s disease scales: is there a need for a new multi-domain
scale for therapy evaluation in medical practice? Alzheimers Res Ther.
2010;2(4):24.
56. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term
outcome. JAMA. 2001;286(17):2120–2127.
57. Smith GS, de Leon MJ, George AE, et al. Topography of crosssectional and longitudinal glucose metabolic deficits in Alzheimer’s
disease. Pathophysiologic implications. Arch Neurol. 1992;49(11):
1142–1150.
58. Kadir A, Andreasen N, Almkvist O, et al. Effect of phenserine treatment
on brain functional activity and amyloid in Alzheimer’s disease. Ann
Neurol. 2008;63(5):621–631.
59. Stefanova E, Wall A, Almkvist O, et al. Longitudinal PET evaluation of
cerebral glucose metabolism in rivastigmine treated patients with mild
Alzheimer’s disease. J Neural Transm. 2006;113(2):205–218.
60. Ihl R, Ferris S, Robert P, Winblad B, Gauthier S, Tennigkeit F. Detecting
treatment effects with combinations of the ADAS-cog items in patients
with mild and moderate Alzheimer’s disease. Int J Geriatr Psychiatry.
2012;27(1):15–21.

61. Pozueta A, Rodríguez-Rodríguez E, Vazquez-Higuera JL, et al. Detection
of early Alzheimer’s disease in MCI patients by the combination of
MMSE and an episodic memory test. BMC Neurol. 2011;11:78.
62. Hardenacke K, Shubina E, Bührle CP, et al. Deep brain stimulation as
a tool for improving cognitive functioning in Alzheimer’s dementia:
a systematic review. Front Psychiatry. 2013;4:159.
63. Hescham S, Lim LW, Jahanshahi A, et al. Deep brain stimulation of the
forniceal area enhances memory functions in experimental dementia:
the role of stimulation parameters. Brain Stimul. 2013;6(1):72–77.
64. Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat
for treatment of Alzheimer’s disease. N Engl J Med. 2013;369(4):
341–350.
65. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab
for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):
311–321.
66. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;
370(4):322–333.
67. Fontaine D, Deudon A, Lemaire JJ, et al. Symptomatic treatment of
memory decline in Alzheimer’s disease by deep brain stimulation:
a feasibility study. J Alzheimers Dis. 2013;34(1):315–323.
68. Kuhn J, Hardenacke K, Lenartz D, et al. Deep brain stimulation of the
nucleus basalis of Meynert in Alzheimer’s dementia. Mol Psychiatry.
2015;20(3):353–360.
69. Gillette-Guyonnet S, Andrieu S, Nourhashemi F, et al. Long-term
progression of Alzheimer’s disease in patients under antidementia drugs.
Alzheimers Dement. 2011;7(6):579–592.
70. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE.
Metabolic reduction in the posterior cingulate cortex in very early
Alzheimer’s disease. Ann Neurol. 1997;42(1):85–94.
71. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology.
2005;64(11):1860–1867.

Dovepress

Open Access Journal of Clinical Trials

Publish your work in this journal
The Open Access Journal of Clinical Trials is an international, peerreviewed, open access journal publishing original research, reports,
editorials, reviews and commentaries on all aspects of clinical trial
design, management, legal, ethical and regulatory issues, case record
form design, data collection, quality assurance and data auditing

methodologies. The manuscript management system is completely
online and includes a very quick and fair peer-review system, which
is all easy to use. Visit http://www.dovepress.com/testimonials.php to
read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/open-access-journal-of-clinical-trials-journal

76

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Open Access Journal of Clinical Trials 2015:7

